Navigation Links
Dendreon Reports Third Quarter 2007 Financial Results
Date:11/15/2007

rent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Revenue $112 $84 $715 $187

Operating expenses:

Research and development 13,449 15,754 54,780 56,995

General and administrative 6,364 5,974 20,458 16,634

Total operating expenses 19,813 21,728 75,2
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... 30, 2014 Grace Century portfolio project, ... Manganello, Chairman of the Board, to the National Stem ... appointment was made by the Ministry of Health on behalf ... , More than a year after Bahamian Parliament ... Prime Minister Perry Christie said the government has completed the ...
(Date:10/30/2014)... severe flooding that devastated a wide swath of Colorado ... bridges, roads and other infrastructure had been upgraded or ... of Colorado Denver. , "People need to understand the ... associate professor of structural engineering at the CU Denver ... the study. "There is an assumption that a bridge ...
(Date:10/27/2014)... -- Kalorama Information says that PCR is demonstrating its ... the United States and is the dominant ... the FDA,s Emergency Use Authorization (EUA) to authorize the emergency ... of the Ebola virus was an indication that the ... IVD industry and its biennial survey on diagnostics markets ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Danaher Corporation (NYSE:,DHR) announced that Executive Vice President ... presenting at the Robert W. Baird Industrial,Conference in ... 1:55 p.m. CST.,The audio will be simultaneously webcast ... a leading manufacturer of Professional,Instrumentation, Medical Technologies, Industrial ...
... ) reports third quarter 2008 results for the period,ended September 30, ... -- Sales increased 3.2% (-1.7% excluding foreign currency) compared to ... the quarter was up $1.7 million to $11.4 million ... of cash was $92.0 million at the end of third quarter ...
... Company,(Nasdaq: PRGO ; TASE) today announced that its ... share, payable on December 16, 2008 to,shareholders of record ... per share represents a ten percent increase over $0.05 ... Company is a leading global healthcare supplier that develops,manufactures ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:10/27/2014)... CA – October 28, 2014 – A new randomized ... proprietary blend of collagen and calcium, KoACT®, was far ... the leaching of calcium from bones and rebuilding new ... PubMed at: http://www.ncbi.nlm.nih.gov/pubmed/25314004 , ahead of print in ... The research was conducted by Bahram H. Arjmandi, PhD, ...
(Date:10/27/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market issues a ... Chief Technology Officer. Mr Tunnell examines the case for ... the variety of new payment solutions being released, consumers ... has its own attributes that promise to make payments ...
(Date:10/27/2014)... results from a safety and immunogenicity study, which ... that a live attenuated enterotoxigenic Escherichia coli ... a novel adjuvant, provided significant protection against disease. ... vaccine/adjuvant combination, which was 58.5 percent efficacious in ... highly rigorous ETEC human challenge model. The vaccine/adjuvant ...
Breaking Biology News(10 mins):New RCT: KoACT® beats calcium and vitamin D for optimal bone strength 2Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 2Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 3Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 4Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea 2
... The University of Manchester have made a surprising finding ... have big implications for research into human healing and ... salamanders have remarkable regenerative capacities, in contrast to mammals, ... tail a new one will regenerate within a week. ...
... Fujian and Shenzhen, China- An international research consortium, led ... completed the first genome sequence of the diamondback moth ... crops. This work provides wider insights into insect adaptation ... sustainable pest management. The latest study was published online ...
... release is available in French and German ... Royal Veterinary College London. Scientists have been able to ... the backbone of early tetrapods, the earliest four-legged animals. High-energy ... to reconstruct the backbones of the 360 million year old ...
Cached Biology News:The secrets of a tadpole's tail and the implications for human healing 2The secrets of a tadpole's tail and the implications for human healing 3The genome of diamondback moth provides new clues for sustainable pest management 2The genome of diamondback moth provides new clues for sustainable pest management 3Scientists reassemble the backbone of life with a particle acceleratorynchrotron X-rays 2Scientists reassemble the backbone of life with a particle acceleratorynchrotron X-rays 3
... The Vibratome Company has joined forces with ... the Vibratome 411301 Tissue Chopper. This tissue ... sections of tissue for metabolic experiments and ... irregular specimens available at biopsy or from ...
... The Vibratome Company has joined forces ... introduce the Vibratome 800 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... design, The Bioactive peptides are molecules of ... biological behaviour or activity which can be ... diagnostic, chemical and agro-food applications. In this ... peptides with superior properties for therapeutic applications. ...
... within neurons in vesicles called synaptosomes. ... synaptic bouton. Synaptosomes may be ... other cellular debris. Abnormalites in neurotransmitter ... pathological condtions. Conditions of release ...
Biology Products: